PMID- 35976208
OWN - NLM
STAT- MEDLINE
DCOM- 20220819
LR  - 20220916
IS  - 1678-9741 (Electronic)
IS  - 0102-7638 (Print)
IS  - 0102-7638 (Linking)
VI  - 37
IP  - 4
DP  - 2022 Aug 16
TI  - Meta-Analysis of Pulmonary Artery Denervation for Treatment of Pulmonary 
      Hypertension.
PG  - 554-565
LID - 10.21470/1678-9741-2020-0533 [doi]
AB  - INTRODUCTION: Pulmonary artery denervation (PADN) can reduce the sympathetic 
      nervous system (SNS) activity, reduce pulmonary artery pressure (PAP), and 
      improve the quality of life in patients with pulmonary hypertension (PH). We 
      conducted a systematic meta-analysis of the effectiveness of PADN in the 
      treatment of PH patients. METHODS: This is a comprehensive literature search 
      including all public clinical trials investigating the effects of PADN on PH. 
      Outcomes were mean pulmonary artery pressure (mPAP), pulmonary vascular 
      resistance (PVR), cardiac output (CO), right ventricular (RV) Tei index, 6-minute 
      walk distance (6MWD), and New York Heart Association (NYHA) cardiac function 
      grading. RESULTS: A total of eight clinical studies with 213 PH patients who 
      underwent PADN were included. Meta-analysis showed that after PADN, mPAP (mean 
      difference [] -12.51, 95% confidence interval [CI] -17.74 to -7.27, P<0.00001) 
      (mmHg) and PVR ( -5.17, 95% CI -7.70 to -2.65, P<0.0001) (Wood unit) decreased 
      significantly, CO ( 0.59, 95% CI 0.32 to 0.86, P<0.0001) (L/min) and 6MWD ( 
      107.75, 95% CI 65.64 to 149.86, P<0.00001) (meter) increased significantly, and 
      RV Tei index ( -0.05, 95% CI -0.28 to 0.17, P=0.63) did not change significantly. 
      Also after PADN, the proportion of NYHA cardiac function grading (risk ratio 
      0.23, 95% CI 0.14 to 0.37, P<0.00001) III and IV decreased significantly. 
      CONCLUSION: This meta-analysis supports PADN as a potential new treatment for PH. 
      Further high-quality randomized controlled studies are needed.
FAU - Zuo, Wanyun
AU  - Zuo W
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, Changsha, Hunan, People's Republic of China.
FAU - Liu, Na
AU  - Liu N
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, Changsha, Hunan, People's Republic of China.
FAU - Xiao, Yunbin
AU  - Xiao Y
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan, People's 
      Republic of China.
FAU - Xie, Yonghui
AU  - Xie Y
AD  - Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan, People's 
      Republic of China.
FAU - Liu, Qiming
AU  - Liu Q
AUID- ORCID: 0000-0002-5213-2668
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central 
      South University, Changsha, Hunan, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220816
PL  - Brazil
TA  - Braz J Cardiovasc Surg
JT  - Brazilian journal of cardiovascular surgery
JID - 101677045
SB  - IM
MH  - Denervation
MH  - Humans
MH  - *Hypertension, Pulmonary/surgery
MH  - *Pulmonary Artery/surgery
MH  - Quality of Life
MH  - Vascular Resistance
PMC - PMC9423798
OTO - NOTNLM
OT  - Heart Ventricles
OT  - Meta-Analysis.
OT  - Pulmonary Artery
OT  - Pulmonary Hypertension
OT  - Quality of Life
OT  - Sympathetic Nervous System
COIS- No conflict of interest.
EDAT- 2022/08/18 06:00
MHDA- 2022/08/20 06:00
PMCR- 2022/07/01
CRDT- 2022/08/17 10:45
PHST- 2022/08/18 06:00 [pubmed]
PHST- 2022/08/20 06:00 [medline]
PHST- 2022/08/17 10:45 [entrez]
PHST- 2022/07/01 00:00 [pmc-release]
AID - 10.21470/1678-9741-2020-0533 [doi]
PST - epublish
SO  - Braz J Cardiovasc Surg. 2022 Aug 16;37(4):554-565. doi: 
      10.21470/1678-9741-2020-0533.